Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
MedImmune LLC
Interleukin-13 (IL-13) is a key mediator in the pathogenesis of established asthmatic disease. Tralokinumab is a human monoclonal antibody that blocks IL-13, which may result in improved control of asthma. This study will determine whether the addition of tralokinumab to standard asthma medications results in a reduced rate of asthma exacerbations in subjects with severe asthma.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18-75 years
Body mass index (BMI) between 16-40 kilogram per square meter (kg/m\^2) at Visit 1
Uncontrolled severe asthma
A chest x-ray with no abnormality
Females of childbearing potential who are sexually active with a non-sterilized male partner must use highly effective contraception from Day 1
Non-sterilized males or sterilized males who are less than or equal to (=\<) 1 year post-vasectomy who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception
You may not be if
Employee of the clinical study site or any other individuals directly involved with the conduct of the study, or immediate family members of such individuals
Pregnant or breastfeeding women
Any other respiratory disease
Previously taken tralokinumab (the study drug)
Current smoker or a history of smoking which would be more than 1 pack per day for 10 years
Known immune deficiency
History of cancer
Hepatitis B, C or Human Immuno-deficiency Virus (HIV)
Any disease which may cause complications whilst taking the study drug.
Clareo Health | A Safety and Efficacy Study of Tralokinumab in Adults With Asthma
